
Peyrac et al. 211 GCA. Relapse in 52% at median 261 days (so 1st year). 83% on GCs at relapse, median dose 6.5mg pred. 36% relapse post-toc discontinuation, at median 133 days. 64% no relapse when toc stopped, at median 511 days @RheumNow #ACR24 Abstr#2652 https://t.co/NqtdDNGGoc https://t.co/mXD8x7O6Ww
Links:
You searched for Characteristics of Relapse and Therapeutic Management in Giant…
https://acrabstracts.org/?post_type=abstracts&s=Characteristics%20of%20Relapse%…
18-11-2024